Instrument Inactif

Autres langues Altimmune Inc NYSE

Actions

US71714G1022

Recherche biotechnologique et médicale

Cours en clôture NYSE
- ^USD	-

30/09	Les développeurs de traitements amaigrissants se bousculent pour conquérir un marché lucratif où la concurrence s’intensifie	RE
29/09	Altimmune, Inc. annonce la nomination de Richard Menziuso au poste de directeur du contrôle financier mondial et de responsable principal de la comptabilité, avec prise de fonctions le 29 septembre 2026	CI

Autres langues

30/09	Weight-loss drug developers line up to tap lucrative market as competition heats up
29/09	Altimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026
23/09	Altimmune to Participate in Stifel Cardiometabolic Forum
21/09	Weight-loss drug developers line up to tap lucrative market as competition heats up
03/09	Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
12/08	Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Altimmune Announces Second Quarter 2026 Financial Results and Business Update
05/08	Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
03/08	Altimmune Begins Patient Enrollment in Phase 3 Pemvidutide Trial for MASH
03/08	Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
03/08	Altimmune, Inc. Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
28/07	Altimmune Announces Positive Topline Results from Reclaim Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
28/07	Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study
28/07	Altimmune Shares Jump Premarket After Positive Results in Phase 2 Trial of Pemvidutide
28/07	Altimmune drug cuts heavy drinking in mid-stage trial for alcohol use disorder
28/07	Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
22/07	Certain Stock Options of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.
22/07	Certain Common Stock of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.
22/07	Certain Pre-Funded Warrants of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.
22/07	Certain Restricted Stock Units of Altimmune, Inc. are subject to a Lock-Up Agreement Ending on 22-JUL-2026.
07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
29/06	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark
29/06	Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell 2500 Growth Benchmark
29/06	Altimmune, Inc.(NasdaqGM:ALT) added to Russell 2000 Value Benchmark
29/06	Altimmune, Inc.(NasdaqGM:ALT) added to Russell Microcap Value Benchmark Index